239 related articles for article (PubMed ID: 19461887)
1. Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy.
Davé UP; Akagi K; Tripathi R; Cleveland SM; Thompson MA; Yi M; Stephens R; Downing JR; Jenkins NA; Copeland NG
PLoS Genet; 2009 May; 5(5):e1000491. PubMed ID: 19461887
[TBL] [Abstract][Full Text] [Related]
2. Ectopic retroviral expression of LMO2, but not IL2Rgamma, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy.
Pike-Overzet K; de Ridder D; Weerkamp F; Baert MR; Verstegen MM; Brugman MH; Howe SJ; Reinders MJ; Thrasher AJ; Wagemaker G; van Dongen JJ; Staal FJ
Leukemia; 2007 Apr; 21(4):754-63. PubMed ID: 17268520
[TBL] [Abstract][Full Text] [Related]
3. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.
Hacein-Bey-Abina S; Von Kalle C; Schmidt M; McCormack MP; Wulffraat N; Leboulch P; Lim A; Osborne CS; Pawliuk R; Morillon E; Sorensen R; Forster A; Fraser P; Cohen JI; de Saint Basile G; Alexander I; Wintergerst U; Frebourg T; Aurias A; Stoppa-Lyonnet D; Romana S; Radford-Weiss I; Gross F; Valensi F; Delabesse E; Macintyre E; Sigaux F; Soulier J; Leiva LE; Wissler M; Prinz C; Rabbitts TH; Le Deist F; Fischer A; Cavazzana-Calvo M
Science; 2003 Oct; 302(5644):415-9. PubMed ID: 14564000
[TBL] [Abstract][Full Text] [Related]
4. LMO2 and IL2RG synergize in thymocytes to mimic the evolution of SCID-X1 gene therapy-associated T-cell leukaemia.
Ruggero K; Al-Assar O; Chambers JS; Codrington R; Brend T; Rabbitts TH
Leukemia; 2016 Sep; 30(9):1959-62. PubMed ID: 27256700
[No Abstract] [Full Text] [Related]
5. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.
Hacein-Bey-Abina S; Garrigue A; Wang GP; Soulier J; Lim A; Morillon E; Clappier E; Caccavelli L; Delabesse E; Beldjord K; Asnafi V; MacIntyre E; Dal Cortivo L; Radford I; Brousse N; Sigaux F; Moshous D; Hauer J; Borkhardt A; Belohradsky BH; Wintergerst U; Velez MC; Leiva L; Sorensen R; Wulffraat N; Blanche S; Bushman FD; Fischer A; Cavazzana-Calvo M
J Clin Invest; 2008 Sep; 118(9):3132-42. PubMed ID: 18688285
[TBL] [Abstract][Full Text] [Related]
6. The LMO2 T-cell oncogene is activated via chromosomal translocations or retroviral insertion during gene therapy but has no mandatory role in normal T-cell development.
McCormack MP; Forster A; Drynan L; Pannell R; Rabbitts TH
Mol Cell Biol; 2003 Dec; 23(24):9003-13. PubMed ID: 14645513
[TBL] [Abstract][Full Text] [Related]
7. Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy.
Aiuti A; Cassani B; Andolfi G; Mirolo M; Biasco L; Recchia A; Urbinati F; Valacca C; Scaramuzza S; Aker M; Slavin S; Cazzola M; Sartori D; Ambrosi A; Di Serio C; Roncarolo MG; Mavilio F; Bordignon C
J Clin Invest; 2007 Aug; 117(8):2233-40. PubMed ID: 17671653
[TBL] [Abstract][Full Text] [Related]
8. Identification of a high incidence region for retroviral vector integration near exon 1 of the LMO2 locus.
Yamada K; Tsukahara T; Yoshino K; Kojima K; Agawa H; Yamashita Y; Amano Y; Hatta M; Matsuzaki Y; Kurotori N; Wakui K; Fukushima Y; Osada R; Shiozawa T; Sakashita K; Koike K; Kumaki S; Tanaka N; Takeshita T
Retrovirology; 2009 Sep; 6():79. PubMed ID: 19725963
[TBL] [Abstract][Full Text] [Related]
9. Chance or necessity? Insertional mutagenesis in gene therapy and its consequences.
Baum C; von Kalle C; Staal FJ; Li Z; Fehse B; Schmidt M; Weerkamp F; Karlsson S; Wagemaker G; Williams DA
Mol Ther; 2004 Jan; 9(1):5-13. PubMed ID: 14741772
[TBL] [Abstract][Full Text] [Related]
10. Review: Oncogenic Insertional Mutagenesis as a Consequence of Retroviral Gene Therapy for X-Linked Severe Combined Immunodeficiency Disease.
Ahmed B; Zafar M; Qadir MI
Crit Rev Eukaryot Gene Expr; 2019; 29(6):511-520. PubMed ID: 32422006
[TBL] [Abstract][Full Text] [Related]
11. A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells.
Zhou S; Mody D; DeRavin SS; Hauer J; Lu T; Ma Z; Hacein-Bey Abina S; Gray JT; Greene MR; Cavazzana-Calvo M; Malech HL; Sorrentino BP
Blood; 2010 Aug; 116(6):900-8. PubMed ID: 20457870
[TBL] [Abstract][Full Text] [Related]
12. An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation.
Ryu BY; Evans-Galea MV; Gray JT; Bodine DM; Persons DA; Nienhuis AW
Blood; 2008 Feb; 111(4):1866-75. PubMed ID: 17991809
[TBL] [Abstract][Full Text] [Related]
13. A novel model of SCID-X1 reconstitution reveals predisposition to retrovirus-induced lymphoma but no evidence of gammaC gene oncogenicity.
Scobie L; Hector RD; Grant L; Bell M; Nielsen AA; Meikle S; Philbey A; Thrasher AJ; Cameron ER; Blyth K; Neil JC
Mol Ther; 2009 Jun; 17(6):1031-8. PubMed ID: 19337236
[TBL] [Abstract][Full Text] [Related]
14. Identification of genes potentially involved in LMO2-induced leukemogenesis.
Davenport J; Neale GA; Goorha R
Leukemia; 2000 Nov; 14(11):1986-96. PubMed ID: 11069036
[TBL] [Abstract][Full Text] [Related]
15. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients.
Howe SJ; Mansour MR; Schwarzwaelder K; Bartholomae C; Hubank M; Kempski H; Brugman MH; Pike-Overzet K; Chatters SJ; de Ridder D; Gilmour KC; Adams S; Thornhill SI; Parsley KL; Staal FJ; Gale RE; Linch DC; Bayford J; Brown L; Quaye M; Kinnon C; Ancliff P; Webb DK; Schmidt M; von Kalle C; Gaspar HB; Thrasher AJ
J Clin Invest; 2008 Sep; 118(9):3143-50. PubMed ID: 18688286
[TBL] [Abstract][Full Text] [Related]
16. The role of LMO2 in development and in T cell leukemia after chromosomal translocation or retroviral insertion.
Nam CH; Rabbitts TH
Mol Ther; 2006 Jan; 13(1):15-25. PubMed ID: 16260184
[TBL] [Abstract][Full Text] [Related]
17. Critical variables affecting clinical-grade production of the self-inactivating gamma-retroviral vector for the treatment of X-linked severe combined immunodeficiency.
van der Loo JC; Swaney WP; Grassman E; Terwilliger A; Higashimoto T; Schambach A; Hacein-Bey-Abina S; Nordling DL; Cavazzana-Calvo M; Thrasher AJ; Williams DA; Reeves L; Malik P
Gene Ther; 2012 Aug; 19(8):872-6. PubMed ID: 22551777
[TBL] [Abstract][Full Text] [Related]
18. A modified γ-retrovirus vector for X-linked severe combined immunodeficiency.
Hacein-Bey-Abina S; Pai SY; Gaspar HB; Armant M; Berry CC; Blanche S; Bleesing J; Blondeau J; de Boer H; Buckland KF; Caccavelli L; Cros G; De Oliveira S; Fernández KS; Guo D; Harris CE; Hopkins G; Lehmann LE; Lim A; London WB; van der Loo JC; Malani N; Male F; Malik P; Marinovic MA; McNicol AM; Moshous D; Neven B; Oleastro M; Picard C; Ritz J; Rivat C; Schambach A; Shaw KL; Sherman EA; Silberstein LE; Six E; Touzot F; Tsytsykova A; Xu-Bayford J; Baum C; Bushman FD; Fischer A; Kohn DB; Filipovich AH; Notarangelo LD; Cavazzana M; Williams DA; Thrasher AJ
N Engl J Med; 2014 Oct; 371(15):1407-17. PubMed ID: 25295500
[TBL] [Abstract][Full Text] [Related]
19. Functional interactions between Lmo2, the Arf tumor suppressor, and Notch1 in murine T-cell malignancies.
Treanor LM; Volanakis EJ; Zhou S; Lu T; Sherr CJ; Sorrentino BP
Blood; 2011 May; 117(20):5453-62. PubMed ID: 21427293
[TBL] [Abstract][Full Text] [Related]
20. Sola dosis facit venenum. Leukemia in gene therapy trials: a question of vectors, inserts and dosage?
Staal FJ; Pike-Overzet K; Ng YY; van Dongen JJ
Leukemia; 2008 Oct; 22(10):1849-52. PubMed ID: 18769449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
